Economic, clinical, and humanistic burden associated with major depressive disorder with prominent anhedonia in the United States: analysis of Medical Expenditure Panel Survey
Journal of Affective Disorders · 2026
DOI: 10.1016/j.jad.2025.120147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Affective Disorders, 2026. Verfasst von Hrishikesh Kale und 5 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson, Titusville, NJ, USA. Electronic address: hkale@its.jnj.com. Hauptthemen laut MEDLINE: Major Depressive Disorder, Anhedonia, Health Expenditures, Cost of Illness. Die Arbeit nennt 54 Literaturangaben. Gefördert von: Johnson and Johnson, Janssen Scientific Affairs LLC.
Abstract (Originalsprache)
BACKGROUND: Anhedonia is a core symptom of major depressive disorder (MDD). However, the burden of prominent anhedonia in patients with MDD is poorly understood. METHODS: In this cross-sectional study, adults (≥18 years) with and without MDD were identified from the Medical Expenditure Panel Survey (2016-2019). Patients with MDD were classified based on the level of anhedonia, identified using the first item of the Patient Health Questionnaire (PHQ)-2, as prominent (MDD-ANH) or other-MDD. The MDD-ANH, other-MDD, and non-MDD cohorts were propensity-score weighted based on baseline characteristics. Use of healthcare services, costs, lost productivity, and health-related quality of life (HRQoL) were compared across cohorts. RESULTS: A total of 5112 respondents with MDD had a valid response for anhedonia per the first item of PHQ-2 (MDD-ANH, n = 1075; other-MDD, n = 4037); 75,502 respondents were identified as non-MDD. Psychotropic polypharmacy was higher in respondents with MDD-ANH than those with other-MDD (43.2 % vs. 27.8 %; p = 0.01). Respondents with MDD-ANH had higher mean office/outpatient and emergency department visits than other-MDD and non-MDD (all p < 0.01). Mean total all-cause healthcare costs were higher in MDD-ANH ($10,353) than other-MDD ($7489) and non-MDD ($5381) (all p < 0.01). HRQoL was lower among respondents with MDD-ANH than those with other-MDD and non-MDD (all p < 0.01). CONCLUSION: These findings suggest a substantial unmet need in patients with MDD-ANH. Treatments that specifically target anhedonia are needed to improve clinical outcomes, quality of life and reduce economic burden in patients with MDD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Johnson & Johnson, Titusville, NJ, USA. Electronic address: hkale@its.jnj.com.
- PPD™ Evidera™ Real-World Data & Scientific Solutions, Thermo Fisher Scientific, Waltham, MA, USA.
- Johnson & Johnson, Titusville, NJ, USA.
- SUNY Upstate Medical University, Syracuse, NY, USA.
Förderung
- Johnson and Johnson
- Janssen Scientific Affairs LLC
Zitieren
APA
Kale, H., Ganz, M. L., Ghosh, R., Saiontz-Martinez, C., Drissen, T., & Cutler, A. J. (2026). Economic, clinical, and humanistic burden associated with major depressive disorder with prominent anhedonia in the United States: analysis of Medical Expenditure Panel Survey. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.120147
Vancouver
Kale H, Ganz ML, Ghosh R, Saiontz-Martinez C, Drissen T, Cutler AJ. Economic, clinical, and humanistic burden associated with major depressive disorder with prominent anhedonia in the United States: analysis of Medical Expenditure Panel Survey. Journal of Affective Disorders. 2026. doi:10.1016/j.jad.2025.120147
BibTeX
@article{Kale2026,
author = {Kale, Hrishikesh and Ganz, Michael L and Ghosh, Rajrupa and Saiontz-Martinez, Cynthia and Drissen, Tiina and Cutler, Andrew J},
title = {Economic, clinical, and humanistic burden associated with major depressive disorder with prominent anhedonia in the United States: analysis of Medical Expenditure Panel Survey},
journal = {Journal of Affective Disorders},
year = {2026},
doi = {10.1016/j.jad.2025.120147}
}
EUVIMED